14 July 2025NewsAmericasEva Ehlich, Maiwald | Lisa Flanagan, Regeneron | Christina Rodrigo, Vertex Pharmaceuticals | Manja Epping, Taylor Wessing
WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
This LSPN panel features experts from Maiwald, Regeneron, Vertex Pharmaceuticals, and Taylor Wessing discussing the impact of increased transparency requirements in clinical trials and their effects on the global patent system. The session focuses on recent regulatory changes, especially in Europe, and the challenges they present for IP protection.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
18 May 2026 LSIPR’s senior reporter Marisa Woutersen speaks with the director of IP at Kymera Therapeutics about the realities of in-house IP leadership and the growing challenge of “fast followers” in biotech.
14 May 2026 Isomorphic Labs said the funding round, led by venture firm Thrive Capital, would be used to further its drug design engine and support hiring targets.
14 May 2026 The agreement is the latest in a string of major deals between Hengrui and multinational drugmakers, and will see the parties jointly develop assets while licensing others.